Genetic alterations in the breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) pathway comprise the largest number of relevant genomic alterations in high-grade ovarian serous cancers (HGSCs) [19,20]. The gene discussed is BRCA2; the disease is breast carcinoma.